A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis

PHASE2UnknownINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

February 29, 2012

Conditions
Ulcerative ColitisLarge IntestineDiarrheaAbdominal Pain
Interventions
DRUG

LT-02

Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks

DRUG

placebo

placebo

Trial Locations (26)

20148

Gastroenterologische Praxis, Hamburg

21339

City Hospital Lueneburg, Lüneburg

24105

Universitaetsklinikum Schleswig-Holstein, Kiel

32423

Gastroenterologisches Zentrum, Minden

38216

City Hospital Braunschweig, Braunschweig

50009

Kaunas Medical University Hospital , Department of Endoscopy, Kaunas

Kaunas Medical University Hospital, Department of Gastroenterology, Kaunas

58507

Internistische Facharztpraxis, Lüdenscheid

60318

Interdisziplinäres Crohn&Colitis Studienzentrum, Frankfurt am Main

66421

University Clinics des Saarlandes, Homburg/Saar

67067

Internistische Gemeinschaftspraxis, Ludwigshafen

69120

University Clinic Heidelberg, Heidelberg

76213

Siauliai District Hospital, Šiauliai

76530

Gastroenterologische Praxis, Baden-Baden

89070

Universitaetsklinikum Ulm, Ulm

92288

Klaipeda Seamen Hospital, Klaipėda

300002

Algomed Policlinic Timisoara, Timișoara

300594

Policlinica Dr. Citu, Timișoara

410163

Cabinet Medical Individual Dr. Tirnaveanu, Oradea

Unknown

Robert-Bosch-Krankenhaus, Stuttgart

04103

UK Leipzig AOR, Klinik für Gastroenterologie und Rheumatologie,, Leipzig

04105

Internistische Gemeinschaftspraxis fuer Verdauungserkrankungen, Leipzig

07743

Universitaetsklinikum Jena, Jena

01102

Santariskes Clinics Centras, Vilnius

020125

Clinical Hospital Colentina, Bucharest

021978

SC Endocenter Medicina Integrativa Bucuresti, Bucharest

Sponsors
All Listed Sponsors
lead

Lipid Therapeutics GmbH

INDUSTRY